Tetra Bio Pharma Inc TBPMQ

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc

<< Previous

Bullboard Posts

Next >>

Post by SamV21on Nov 17, 2021 3:00am

507 Views

Post# 34134877

We have been there 5 times before no results, no difference

Tetra Receives its 4th FDA Orphan Drug Designation

04/16/2020

Tetra's PPP004 cannabinoid drug receives Orphan Drug Designation for the Treatment of Epidermolysis Bullosa.
Here we go again .
Another abandoned item that was going to put Tetra on the drug pharma map April 2020 , that was going to be the break out year. remember.Facts
Pump and Dum

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks